Atkins Robert C, Polkinghorne Kevan R, Briganti Esther M, Shaw Jonathan E, Zimmet Paul Z, Chadban Steven J
Department of Nephrology, Monash Medical Centre, Victoria, Australia.
Kidney Int Suppl. 2004 Nov(92):S22-4. doi: 10.1111/j.1523-1755.2004.09206.x.
Albuminuria is an important predictor of risk of progressive renal disease, cardiovascular disease, and mortality; however, the prevalence in the general population is not well defined. We determined estimates of the population prevalence and associations of microalbuminuria and macroalbuminuria in Australian adults; 11,247 Australians aged > or = 25 years living in 42 randomly selected population clusters were tested for albuminuria (spot urine albumin:creatinine (mg/mmol): normal < 3.4, microalbuminuria 3.4 to 34, macroalbuminuria > 34).
Prevalence of micro- and macroalbuminuria were assessed with age, sex, obesity, smoking, hypertension (> or = 140/90 mm Hg or known diagnosis on treatment), glucose metabolism status (WHO criteria according to fasting glucose and oral glucose tolerance test), ischemic heart and cerebrovascular disease, and low glomerular filtration rate (calculated glomerular filtration rate < 60 mL/min/1.73m2).
Microalbuminuria and macroalbuminuria proteinuria were present in 6.0% and 0.6% of the population, respectively. The majority of subjects with microalbuminuria (64%) and macroalbuminuria (76%) had hypertension, and approximately half of those with albuminuria had abnormal glucose metabolism. Of all participants with microalbuminuria, 25.9% had normal blood pressure and glucose metabolism, and in this group, alternative associations of microalbuminuria included obesity (13.5%), smoking (20.7%), and low glomerular filtration rate (12.3%).
Albuminuria is present in a small percentage of the general adult population, but is highly prevalent in subjects with hypertension and/or abnormal glucose metabolism. The majority of cases of microalbuminuria and macroalbuminuria in the general population are among those with hypertension.
蛋白尿是进展性肾病、心血管疾病及死亡风险的重要预测指标;然而,普通人群中的患病率尚不明确。我们测定了澳大利亚成年人中微量白蛋白尿和大量白蛋白尿的人群患病率及其相关性;对居住在42个随机选取的人群聚集区中11247名年龄≥25岁的澳大利亚人进行了蛋白尿检测(随机尿白蛋白:肌酐(mg/mmol):正常<3.4,微量白蛋白尿3.4至34,大量白蛋白尿>34)。
根据年龄、性别、肥胖、吸烟、高血压(≥140/90 mmHg或已知诊断正在接受治疗)、糖代谢状态(根据空腹血糖和口服葡萄糖耐量试验的WHO标准)、缺血性心脏病和脑血管疾病以及低肾小球滤过率(计算的肾小球滤过率<60 mL/min/1.73m²)评估微量和大量白蛋白尿的患病率。
微量白蛋白尿和大量白蛋白尿蛋白尿在人群中的患病率分别为6.0%和0.6%。大多数微量白蛋白尿(64%)和大量白蛋白尿(76%)患者患有高血压,且约一半蛋白尿患者存在糖代谢异常。在所有微量白蛋白尿参与者中,25.9%血压和糖代谢正常,在这一组中,微量白蛋白尿的其他相关因素包括肥胖(13.5%)、吸烟(20.7%)和低肾小球滤过率(12.3%)。
蛋白尿在普通成年人群中的比例较小,但在高血压和/或糖代谢异常的患者中非常普遍。普通人群中大多数微量白蛋白尿和大量白蛋白尿病例存在于高血压患者中。